Authors: K B Hoover C G Miller N C Galante C B Langman
Publish Date: 2015/05/09
Volume: 26, Issue: 10, Pages: 2441-2447
Abstract
This study compared the effects of pediatric acne treatment with two isotretinoin formulations on bone mineral density We demonstrated no difference in the effect of the two formulations No effect on pediatric bone mineral density was identified for either formulationIsotretinoin 13cisretinoic acid is a treatment for recalcitrant nodular acne with a purported effect on bone mineral density BMD The side effects of isotretinoin on vertebral bone were evaluated to assess the safety of a new FDAapproved isotretinoin formulation Lidoseisotretinoin CipIsoThis doubleblind randomized phase III active control parallelgroup multicenter study compared the safety efficacy and noninferiority of CIPIso to a marketed reference product Accutane® in severe recalcitrant nodular acne subjects Three hundred fiftyeight pediatric male and female subjects aged between 12 and 17 years underwent 20 weeks of treatment with PA lumbar spine dual Xray absorptiometry DXA measurements obtained for bone mineral density BMD and Zscores 55 months apart on visits 1 and 8 One hundred sixtyeight of 358 subjects had height adjusted Zscores HAZ calculatedThere was no difference in the least squares LS mean Zscore or HAZ of the two drugs at visit 1 or 8 The mean and LS mean Zscore and HAZ were greater than zero at visits 1 and 8 for both drugs The change in the LS mean spine Zscore but not HAZ between visits was statistically significant for both drugs There was a mean increase in BMD g/cm2 for both products between visitsThere is no difference in the effect of two formulations of isotretinoin on spine bone density after 6 months of treatment BMD increased and the small change in spine Zscore over treatment disappeared after height adjustment Mean positive Zscores and HAZ in the study were likely due to the exclusion of low and inclusion of high Zscore subjectsKevin B Hoover was a consultant for BioClinica Inc on this study Colin G Miller and Nicholas C Galante were employees of BioClinica Inc at the time the study was performed Craig B Langman declares he has no conflict of interest This study was sponsored by Cipher Pharmaceuticals Inc
Keywords: